Inactive Instrument

Analyst Reco. Tandem Diabetes Care Inc Nasdaq

Equities

US8753721047

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

Oppenheimer Adjusts Price Target on Tandem Diabetes Care to $58 From $47, Maintains Outperform Rating	06-10	MT
Tandem Diabetes Care Insider Sold Shares Worth $258,400, According to a Recent SEC Filing	06-03	MT
Redburn Atlantic Starts Tandem Diabetes Care With Buy Rating, $60 Price Target	05-30	MT
Lake Street Adjusts Price Target on Tandem Diabetes Care to $75 From $60, Maintains Buy Rating	05-22	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $55 From $45, Maintains Buy Rating	05-22	MT
Citi Upgrades Tandem Diabetes Care to Buy, Price Target at $57	05-22	MT
Social Buzz: Wallstreetbets Stocks Mostly Lower Premarket Wednesday; Hims & Hers Health, Tesla to Decline	05-22	MT
UBS Adjusts Price Target on Tandem Diabetes Care to $40 From $28, Maintains Neutral Rating	05-03	MT
Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target is $45	04-29	MT
Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45	04-25	MT
Stifel Adjusts Price Target on Tandem Diabetes Care to $40 From $37, Maintains Buy Rating	04-23	MT
Stifel Upgrades Tandem Diabetes Care to Buy From Hold, Adjusts Price Target to $37 From $24	03-26	MT
Citigroup Raises Price Target on Tandem Diabetes Care to $31 From $25, Keeps Neutral Rating	03-15	MT
UBS Raises Tandem Diabetes Care Price Target to $28 From $18, Maintains Neutral Rating	01-22	MT
TD Cowen Raises Tandem Diabetes Care Price Target to $35 From $22, Maintains Outperform Rating	01-18	MT
BofA Securities Cuts Price Target on Tandem Diabetes Care to $18 From $33, Keeps Underperform Rating	23-10-18	MT
Citigroup Cuts Tandem Diabetes Care's Price Target to $23 From $31, Keeps Neutral Rating	23-10-02	MT
Jefferies Adjusts Price Target on Tandem Diabetes Care to $45 From $47, Maintains Buy Rating	23-10-02	MT
Citigroup Adjusts Price Target on Tandem Diabetes Care to $31 From $33, Maintains Neutral Rating	23-08-21	MT
Baird Trims Price Target on Tandem Diabetes Care to $32 From $33, Maintains Neutral Rating	23-08-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Tandem Diabetes Care Inc Nasdaq

Equities

US8753721047

Analyst Reco.

Filters